Most recent by Anita Gupta, DO, PharmD, MPP, GMP, FASA
FDA approves nonopioid Journavx for moderate to severe acute pain
The FDA has approved Journavx 50 mg oral tablets for the treatment of moderate to severe acute pain in adults, according to a press release.
Community-engaged intervention reduces polysubstance overdose deaths by 37%
A community coalition-engaged intervention led to a statistically significant reduction in overdose deaths involving any opioid and psychostimulants other than cocaine, according to a study published in JAMA Network Open.
Fatal drug overdose deaths down as much as 10%, although reasons why remain unclear
Fatal and nonfatal drug overdoses experienced “unprecedented” decreases of 10% to 20% from last year, which could be due to factors like increased naloxone availability, according to researchers.
$1 billion Bloomberg gift allows most med students at Johns Hopkins to attend for free
Bloomberg Philanthropies announced that it has donated $1 billion to make Johns Hopkins University’s medical school free for most of its students seeking an MD.
CDC: Drug overdose deaths decreased in 2023
Drug overdose deaths in the United States decreased in 2023 for the first time in half a decade, preliminary CDC data showed.
Program boosts PCPs’ confidence in prescribing OUD treatment
A medication-assisted treatment, or MAT, supplemental training program improved primary care physicians’ confidence and willingness to implement MAT for opioid use disorder, a recent study found.
CDC updates clinical guidance on prescribing opioids for pain
The CDC has released updated and expanded clinical practice guidance on prescribing opioids to patients with short- and long-term pain.
'A long way to go': Nearly 90% of people with opioid use disorder do not receive medication
The majority of people with opioid use disorder in the United States are not receiving life-saving medication due to multiple barriers to access, according to a study published in the International Journal of Drug Policy.
Opioid tapering significantly increases risk for overdose, mental health crisis
Patients who had their opioids tapered after receiving stable, long-term, higher-dose opioid therapy were at a significantly increased risk for overdose and mental health crisis than those who did not have reduced doses, data showed.
Governments, opioid companies reach $26B agreement
State and local governments across the U.S. have reached an agreement with Johnson & Johnson, McKesson, Cardinal Health and AmerisourceBergen that will provide up to $26 billion to fight the opioid epidemic, the parties involved announced.